IPHA News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

IP

Volume

7.86K

Loading chart

IP

IPHAInnate Pharma S.A. ADS

IPHA

Pay with—

Available Balance0.00

IP

Mkt Cap

$159.7M

Volume

7.86K

Next Earnings

N/A

Chart Earnings News About Insider Filings

Down 25% in 4 Weeks, Here's Why You Should You Buy the Dip in Innate Pharma (IPHA)Innate Pharma (IPHA) has declined 25% over four weeks but shows signs of oversold conditions with an RSI reading of 29.75. Analysts have raised earnings estimates by 32.9% over the past 30 days, and the stock holds a Zacks Rank #2 (Buy) rating, suggesting a potential near-term turnaround.Zacks Investment Research · Oct 5, 2026

A Third Cancer Drug Just Entered the Clinic at an Under-$20-Million CompanyGT Biopharma announced its third cancer drug, GTB-5550, entered Phase 1 clinical trials on May 14, 2026, marking the company's first expansion into solid tumors. Despite having three drugs in human trials—unusual for a micro-cap—the company trades at a significant valuation discount compared to peers, with only ~$9 million in cash and a runway into late 2026. The gap between its scientific promise and market valuation presents both opportunity and substantial risk, with near-term catalysts including clinical data updates and financing announcements expected in H2 2026.Benzinga · Jun 2, 2026

Cutaneous T-Cell Lymphoma Clinical Trial Pipeline Accelerates as 30+ Pharma Companies Rigorously Developing Drugs for Market Entry | DelveInsightOver 30 pharmaceutical companies are actively developing more than 30 pipeline drugs for cutaneous T-cell lymphoma (CTCL), a rare non-Hodgkin lymphoma affecting the skin. Key players including Prescient Therapeutics, Innate Pharma, and others are advancing promising therapies with various mechanisms of action through clinical trials. The market is projected to grow steadily driven by increasing adoption of targeted and immunotherapies, though limited patient populations and high treatment costs remain challenges.GlobeNewswire Inc. · May 21, 2026

Peripheral T-Cell Lymphoma Market to Witness Significant Expansion at a CAGR of 7% During the Forecast Period (2026–2036) Amid Advancing Treatment Landscape | DelveInsightThe peripheral T-cell lymphoma (PTCL) treatment market is projected to grow at a 7% CAGR through 2036, driven by increasing disease incidence and expanding patient populations. The market was valued at USD 800 million in 2025, with the US accounting for 68% of the market. Multiple emerging therapies from major pharmaceutical companies are expected to transform the treatment landscape, with ADCETRIS currently holding the largest market share at over USD 300 million.GlobeNewswire Inc. · Apr 27, 2026

Arvind Sood joins Coherus Oncology as Chief Strategy and Corporate Affairs OfficerCoherus Oncology announced the appointment of Arvind Sood as Chief Strategy and Corporate Affairs Officer, focusing on advancing innovative cancer therapeutics and driving revenues for LOQTORZI®.GlobeNewswire Inc. · Nov 6, 2025

Non-Hodgkin’s Lymphoma Market Forecast to Surge with Growing Adoption of Targeted and Cell-Based Therapies | DelveInsightThe non-Hodgkin's lymphoma market is expected to grow significantly between 2025-2034, driven by increasing incidence, advancements in targeted therapies, emerging treatments, and improved early detection efforts.GlobeNewswire Inc. · Jul 24, 2025

Cutaneous T-cell Lymphoma Market Anticipates Impressive Growth Trajectory at a CAGR of 7.1% During the Study Period (2020–2034) | DelveInsightThe cutaneous T-cell lymphoma market is expected to grow at a 7.1% CAGR from 2020-2034, driven by research advancements, increasing prevalence, and emerging therapies targeting this rare lymphoma.GlobeNewswire Inc. · Jul 21, 2025

All You Need to Know About Innate Pharma (IPHA) Rating Upgrade to BuyInnate Pharma (IPHA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.Zacks Investment Research · Apr 10, 2024

Innate Pharma (IPHA) Gains as FDA Lifts Hold on Lymphoma StudyInnate Pharma (IPHA) stock moves up in the pre-market hours as the FDA lifts the partial clinical hold placed on a study evaluating lacutamab for Sezary syndrome.Zacks Investment Research · Jan 4, 2024

Innate (IPHA) Gains as Blood Cancer Drug Gets Fast Track TagInnate (IPHA) and Sanofi's SAR'579 / IPH6101 get Fast Track Designation in the United States for the treatment of hematological malignancies.Zacks Investment Research · Jun 9, 2023

to start trading

IP

IPHAInnate Pharma S.A. ADS

IPHA

Pay with—

Available Balance0.00

Your PositionYou don't own any IPHA yet.

Related Tickers

Earnings